Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 7:16 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1297–1320 of 1,667 matching trials from the live ClinicalTrials.gov search.
Conditions
Apathy, Stroke, Stroke Sequelae, Stroke/Brain Attack, Stroke/ Cerebrovascular Accident (Ischemic or Hemorrhagic), Motivation, Abulia
Interventions
MagVenture MagPro Transcranial Magnetic Stimulation (TMS) System (Active), MagVenture MagPro Transcranial Magnetic Stimulation (TMS) System (Sham), Brainsight Neuronavigation System
Device · Other
Lead sponsor
Medical University of South Carolina
Other
Eligibility
40 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Charleston, South Carolina
Conditions
Breast Neoplasms, Triple Negative Breast Neoplasms, HR Low-Positive/HER2-Negative Breast Neoplasms
Interventions
Sacituzumab tirumotecan, Pembrolizumab, Rescue Medication, Carboplatin, Paclitaxel, Doxorubicin, Epirubicin, Cyclophosphamide, Capecitabine, Olaparib
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
2,400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2034
U.S. locations
64
States / cities
Gilbert, Arizona • Phoenix, Arizona • Tucson, Arizona + 54 more
Conditions
Head and Neck Cancer
Interventions
Cisplatin or carboplatin, Intensity-modulated radiation therapy (IMRT) or Intensity-modulated proton therapy (IMPT), Pembrolizumab, LymphDetect assay, Surgery +/- neoadjuvant pembrolizumab
Drug · Radiation · Diagnostic Test + 1 more
Lead sponsor
Kevin Contrera
Other
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Conditions
Melanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck, Urothelial Carcinoma, Renal Cell Carcinoma, Small-cell Lung Cancer, Cutaneous Squamous Cell Carcinoma, Anal Squamous Cell Carcinoma, Merkel Cell Carcinoma
Interventions
GEN-011, IL-2, Fludarabine, Cyclophosphamide
Biological · Drug
Lead sponsor
Genocea Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
8
States / cities
Gilbert, Arizona • Tampa, Florida • Chicago, Illinois + 4 more
Conditions
Breast Cancer Triple Negative
Interventions
Mirvetuximab Soravtansine (IMGN853)
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Cannabis
Interventions
CBD 1mg/Kg, CBD 2mg/Kg, CBD 4mg/Kg, Placebo CBD
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 55 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Obesity & Overweight, Cardiometabolic Health Indicators
Interventions
GLP-1 dose reduction, non-GLP weight loss medication, Maintenance of GLP-1 dose, Resistance exercise regimen, Lifestyle/nutrition counseling
Drug · Behavioral
Lead sponsor
Jing Luo
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Completed Phase 4 Interventional Accepts healthy volunteers

How Does Magnesium Status Influence Calcium Homeostasis?

NCT01593501
Conditions
Magnesium Deficiency, Calcium Metabolism Disorders
Interventions
vitamin D3
Dietary Supplement
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
30 Years to 75 Years · Female only
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Madison, Wisconsin
Conditions
Lymphoma, Large B-Cell, Diffuse
Interventions
Durvalumab, Rituximab, Doxorubicin, Vincristine, Cyclophosphamide, Prednisone, Lenalidomide
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
7
States / cities
Gilbert, Arizona • Fort Wayne, Indiana • Rochester, Minnesota + 4 more
Conditions
Diabetes Mellitus, Type 2
Interventions
Placebo identical to BI10773 high dose, BI 10773, BI 10773 open label, Placebo identical to BI10773 low dose, Placebo identical to Sitagliptin 100mg, BI10773, Sitagliptin
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
986 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
27
States / cities
Mesa, Arizona • Phoenix, Arizona • Hot Springs, Arkansas + 23 more
Conditions
Type 2 Diabetes Mellitus With Diabetic Nephropathy
Interventions
IW-1973, Placebo
Drug
Lead sponsor
Akebia Therapeutics
Industry
Eligibility
25 Years to 75 Years
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
54
States / cities
Birmingham, Alabama • Chula Vista, California • Fullerton, California + 42 more
Conditions
Brain Cancer
Interventions
erlotinib, Cytoreductive Surgery
Drug · Procedure
Lead sponsor
Andrew B Lassman, MD
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
4
States / cities
Basking Ridge, New Jersey • Commack, New York • New York, New York
Conditions
Pouch, Ileal, Pouches, Ileoanal, Bowel Diseases, Inflammatory
Interventions
Tirzepatide, Loperamide, Diphenoxylate/Atropine
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027
U.S. locations
5
States / cities
Beverly Hills, California • Rochester, Minnesota • St Louis, Missouri + 2 more
Conditions
Oropharyngeal Squamous Cell Carcinoma
Interventions
Transoral Robotic Surgery (TORS) or Radiotherapy, Chemotherapy and Low-Dose Radiotherapy, Chemotherapy and High-Dose Radiotherapy, Paclitaxel, Carboplatin
Other · Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Chicago, Illinois
Completed Phase 1 Interventional Accepts healthy volunteers

VNRX-5133 Drug-Drug Interaction in Healthy Adult Volunteers

NCT03332732
Conditions
Bacterial Infections
Interventions
VNRX-5133, VNRX-5022, Metronidazole, Placebo
Drug
Lead sponsor
Venatorx Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Lenexa, Kansas
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Food Effect Study of Febuxostat XR in Healthy Participants

NCT02374164
Conditions
Gout
Interventions
Febuxostat XR
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Austin, Texas
Conditions
Scar Prevention, Scar Reduction
Interventions
Placebo, AZX100
Drug
Lead sponsor
Capstone Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
5
States / cities
Pasadena, California • DeLand, Florida • Orlando, Florida + 2 more
Conditions
COVID-19
Interventions
anti-SARS-CoV-2 convalescent plasma
Biological
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Completed Phase 4 Interventional Results available

Dose Response of a Tubule Occlusion Agent

NCT01075256
Conditions
Dentine Hypersensitivity, Dental Pain
Interventions
5% calcium sodium phosphosilicate toothpaste, 7.5% calcium sodium phosphosilicate toothpaste, Placebo toothpaste
Device
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 50 Years
Enrollment
195 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Fort Wayne, Indiana
Completed Phase 1Phase 2 Interventional Results available

Cyclophosphamide, Abatacept, and Tacrolimus for GvHD Prevention

NCT04503616
Conditions
Graft-versus-host Disease
Interventions
Cyclophosphamide, Abatacept, and Tacrolimus for GvHD Prevention
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
New York, New York
Conditions
HIV Infections
Interventions
DTG + 3TC, TAF based regimen (TBR)
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
743 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
54
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Bakersfield, California + 44 more
Conditions
Insomnia, Attention Deficit Hyperactivity Disorder
Interventions
eszopiclone, Placebo
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
6 Years to 17 Years
Enrollment
486 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
73
States / cities
Birmingham, Alabama • Dothan, Alabama • Chandler, Arizona + 56 more
Conditions
Pulmonary Arterial Hypertension
Interventions
PF-07868489, Placebo for PF-07868489
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
97 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
16
States / cities
Anaheim, California • Costa Mesa, California • Orange, California + 5 more
Conditions
Fibrodysplasia Ossificans Progressiva
Interventions
Palovarotene, midazolam
Drug
Lead sponsor
Clementia Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Cambridge, Massachusetts